463 related articles for article (PubMed ID: 25934691)
1. Transglutaminase Is Required for Epidermal Squamous Cell Carcinoma Stem Cell Survival.
Fisher ML; Keillor JW; Xu W; Eckert RL; Kerr C
Mol Cancer Res; 2015 Jul; 13(7):1083-94. PubMed ID: 25934691
[TBL] [Abstract][Full Text] [Related]
2. Type II transglutaminase stimulates epidermal cancer stem cell epithelial-mesenchymal transition.
Fisher ML; Adhikary G; Xu W; Kerr C; Keillor JW; Eckert RL
Oncotarget; 2015 Aug; 6(24):20525-39. PubMed ID: 25971211
[TBL] [Abstract][Full Text] [Related]
3. Transamidase site-targeted agents alter the conformation of the transglutaminase cancer stem cell survival protein to reduce GTP binding activity and cancer stem cell survival.
Kerr C; Szmacinski H; Fisher ML; Nance B; Lakowicz JR; Akbar A; Keillor JW; Lok Wong T; Godoy-Ruiz R; Toth EA; Weber DJ; Eckert RL
Oncogene; 2017 May; 36(21):2981-2990. PubMed ID: 27941875
[TBL] [Abstract][Full Text] [Related]
4. Transglutaminase-2: evolution from pedestrian protein to a promising therapeutic target.
Agnihotri N; Mehta K
Amino Acids; 2017 Mar; 49(3):425-439. PubMed ID: 27562794
[TBL] [Abstract][Full Text] [Related]
5. Transglutaminase is a tumor cell and cancer stem cell survival factor.
Eckert RL; Fisher ML; Grun D; Adhikary G; Xu W; Kerr C
Mol Carcinog; 2015 Oct; 54(10):947-58. PubMed ID: 26258961
[TBL] [Abstract][Full Text] [Related]
6. Evidence that GTP-binding domain but not catalytic domain of transglutaminase 2 is essential for epithelial-to-mesenchymal transition in mammary epithelial cells.
Kumar A; Xu J; Sung B; Kumar S; Yu D; Aggarwal BB; Mehta K
Breast Cancer Res; 2012 Jan; 14(1):R4. PubMed ID: 22225906
[TBL] [Abstract][Full Text] [Related]
7. Tissue transglutaminase-mediated chemoresistance in cancer cells.
Verma A; Mehta K
Drug Resist Updat; 2007; 10(4-5):144-51. PubMed ID: 17662645
[TBL] [Abstract][Full Text] [Related]
8. Transglutaminase Interaction with α6/β4-Integrin Stimulates YAP1-Dependent ΔNp63α Stabilization and Leads to Enhanced Cancer Stem Cell Survival and Tumor Formation.
Fisher ML; Kerr C; Adhikary G; Grun D; Xu W; Keillor JW; Eckert RL
Cancer Res; 2016 Dec; 76(24):7265-7276. PubMed ID: 27780825
[TBL] [Abstract][Full Text] [Related]
9. Gα(h)/transglutaminase-2 activity is required for maximal activation of adenylylcyclase 8 in human and rat glioma cells.
Obara Y; Yanagihata Y; Abe T; Dafik L; Ishii K; Nakahata N
Cell Signal; 2013 Mar; 25(3):589-97. PubMed ID: 23200849
[TBL] [Abstract][Full Text] [Related]
10. Transglutaminase 2 and NF-κB: an odd couple that shapes breast cancer phenotype.
Brown KD
Breast Cancer Res Treat; 2013 Jan; 137(2):329-36. PubMed ID: 23224146
[TBL] [Abstract][Full Text] [Related]
11. Transglutaminase 2 suppresses apoptosis by modulating caspase 3 and NF-kappaB activity in hypoxic tumor cells.
Jang GY; Jeon JH; Cho SY; Shin DM; Kim CW; Jeong EM; Bae HC; Kim TW; Lee SH; Choi Y; Lee DS; Park SC; Kim IG
Oncogene; 2010 Jan; 29(3):356-67. PubMed ID: 19838207
[TBL] [Abstract][Full Text] [Related]
12. Functional characterization of naturally occurring transglutaminase 2 mutants implicated in early-onset type 2 diabetes.
Salter NW; Ande SR; Nguyen HK; Nyomba BL; Mishra S
J Mol Endocrinol; 2012 Jun; 48(3):203-16. PubMed ID: 22394545
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of Transglutaminase 2 activity increases cisplatin cytotoxicity in a model of human hepatocarcinoma chemotherapy.
Meshram DD; Pike CVS; Coussons PJ
Eur J Pharmacol; 2017 Nov; 815():332-342. PubMed ID: 28943101
[TBL] [Abstract][Full Text] [Related]
14. Tissue transglutaminase induces Epithelial-Mesenchymal-Transition and the acquisition of stem cell like characteristics in colorectal cancer cells.
Ayinde O; Wang Z; Griffin M
Oncotarget; 2017 Mar; 8(12):20025-20041. PubMed ID: 28223538
[TBL] [Abstract][Full Text] [Related]
15. Tissue transglutaminase (TG2) is involved in the resistance of cancer cells to the histone deacetylase (HDAC) inhibitor vorinostat.
Carbone C; Di Gennaro E; Piro G; Milone MR; Pucci B; Caraglia M; Budillon A
Amino Acids; 2017 Mar; 49(3):517-528. PubMed ID: 27761756
[TBL] [Abstract][Full Text] [Related]
16. The complex role of transglutaminase 2 in glioblastoma proliferation.
Gundemir S; Monteagudo A; Akbar A; Keillor JW; Johnson GVW
Neuro Oncol; 2017 Feb; 19(2):208-218. PubMed ID: 27591334
[TBL] [Abstract][Full Text] [Related]
17. Transglutaminase 2 reprogramming of glucose metabolism in mammary epithelial cells via activation of inflammatory signaling pathways.
Kumar S; Donti TR; Agnihotri N; Mehta K
Int J Cancer; 2014 Jun; 134(12):2798-807. PubMed ID: 24477458
[TBL] [Abstract][Full Text] [Related]
18. The transglutaminase 2 cancer cell survival factor maintains mTOR activity to drive an aggressive cancer phenotype.
Chen X; Adhikary G; Newland JJ; Xu W; Ma E; Naselsky W; Eckert RL
Mol Carcinog; 2023 Jan; 62(1):90-100. PubMed ID: 35848131
[TBL] [Abstract][Full Text] [Related]
19. Tissue transglutaminase-2 promotes gastric cancer progression via the ERK1/2 pathway.
Wang X; Yu Z; Zhou Q; Wu X; Chen X; Li J; Zhu Z; Liu B; Su L
Oncotarget; 2016 Feb; 7(6):7066-79. PubMed ID: 26771235
[TBL] [Abstract][Full Text] [Related]
20. IL-1β induces IL-6 production and increases invasiveness and estrogen-independent growth in a TG2-dependent manner in human breast cancer cells.
Oh K; Lee OY; Park Y; Seo MW; Lee DS
BMC Cancer; 2016 Sep; 16(1):724. PubMed ID: 27609180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
